Analysis of the Metabolism of Haloperidol and Its Neurotoxic Pyridinium Metabolite in Patients with Drug-Induced Parkinsonism
| Autor: | K. Igarashi, Kazuhiko Nakamura, I. Fukunishi, Kazuhiko Iwahashi, K. Anemo |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Drug Spectrometry Mass Electrospray Ionization Electrospray media_common.quotation_subject Metabolite Pyridinium Compounds Pharmacology chemistry.chemical_compound Parkinsonian Disorders medicine Haloperidol Humans Biological Psychiatry media_common biology Parkinsonism Metabolism medicine.disease Psychiatry and Mental health Neuropsychology and Physiological Psychology chemistry Biochemistry Schizophrenia biology.protein Female Pyridinium Antipsychotic Agents Chromatography Liquid medicine.drug Neurotrophin |
| Zdroj: | Neuropsychobiology. 44:126-128 |
| ISSN: | 1423-0224 0302-282X |
| DOI: | 10.1159/000054931 |
| Popis: | The blood levels of the neurotrophic drug haloperidol (HP) and its pyridinium metabolite, HPP+, have been analyzed by liquid chromatography/electrospray ionization-mass spectrometry in 10 schizophrenic patients treated with HP, without carbamazepine (HP, oral daily dose of 0.3–0.5 mg/kg body weight for more than 1 year, females, aged 41 ± 8.5 years). There was a significant difference (t-test, d.f. = 8, p (t₀ = 7.2) + level between the 5 patients with (18.5 ± 6.4 ng/ml) and the 5 without (6.3 ± 2.4 ng/ml) severe side effects such as drug-induced parkinsonism (Extrapyramidal Symptom Rating Scale (ESRS) parkinsonism severity scores 2.8 ± 1.5 and 1.8 ± 1.1, respectively). Moreover, it is suggested that vitamin E may be effective for drug-induced parkinsonism through a change in the blood HPP+ level. It is necessary to investigate the HPP+ metabolism in psychiatric patients to avoid severe side effects such as drug-induced parkinsonism and cardiac functional disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|